Fabtech Technologies Ltd
Incorporated in 2018, Fabtech Technologies Ltd is a biopharma engineering company.[1]
- Market Cap ₹ 1,064 Cr.
- Current Price ₹ 240
- High / Low ₹ 263 / 173
- Stock P/E 19.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 22.2 %
- ROE 21.6 %
- Face Value ₹ 10.0
Pros
Cons
- Earnings include an other income of Rs.27.4 Cr.
- Company has high debtors of 168 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology
Part of BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 121 | 257 | 194 | 226 | 327 | |
| 110 | 225 | 169 | 191 | 289 | |
| Operating Profit | 11 | 32 | 25 | 35 | 38 |
| OPM % | 9% | 12% | 13% | 16% | 12% |
| 2 | 4 | 10 | 6 | 27 | |
| Interest | 2 | 3 | 5 | 3 | 2 |
| Depreciation | 0 | 2 | 2 | 2 | 3 |
| Profit before tax | 11 | 31 | 28 | 36 | 60 |
| Tax % | 29% | 25% | 22% | 24% | 23% |
| 8 | 23 | 22 | 27 | 46 | |
| EPS in Rs | 8,040.00 | 84.28 | 78.00 | 92.44 | 14.34 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 24% |
| Last Year: | 22% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 3 | 3 | 3 | 32 | 32 |
| Reserves | 46 | 65 | 86 | 129 | 141 | 162 |
| 9 | 21 | 35 | 13 | 84 | 42 | |
| 70 | 83 | 89 | 125 | 170 | 181 | |
| Total Liabilities | 126 | 172 | 214 | 269 | 427 | 418 |
| 2 | 5 | 4 | 22 | 94 | 79 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 7 | 17 | 20 | 21 | 15 | 25 |
| 116 | 150 | 190 | 226 | 318 | 313 | |
| Total Assets | 126 | 172 | 214 | 269 | 427 | 418 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -9 | -3 | -14 | 61 | -36 | |
| 4 | -9 | 2 | -30 | -20 | |
| 6 | 8 | 12 | -13 | 36 | |
| Net Cash Flow | 1 | -4 | -0 | 18 | -20 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 135 | 120 | 187 | 156 | 168 |
| Inventory Days | 39 | 17 | 69 | 88 | 119 |
| Days Payable | 150 | 136 | 215 | 195 | 198 |
| Cash Conversion Cycle | 25 | 1 | 41 | 49 | 89 |
| Working Capital Days | 15 | 30 | 65 | 63 | 53 |
| ROCE % | 48% | 31% | 28% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1h - Newspaper publication under Regulation 30 and 47 of the SEBI (LODR) Regulations, 2015 regarding Financial Results for the quarter ended June 30, 2025 and for …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - KP Group and Fabtech sign MoU to develop renewable-powered pharma, biotech, healthcare infrastructure across India, Middle East, Africa.
- Unaudited Standalone And Consolidated Financials Results Of The Company For The Quarter Ended June 30, 2025 1d
- Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2025 1d
-
Board Meeting Outcome for Outcome Of Board Meeting- Disclosure Under Regulation 30 And 33 Of The SEBI (LODR) Regulations, 2015
1d - Approved unaudited standalone and consolidated results for quarter June 30 and quarter/half-year Sept 30, 2025; limited review enclosed.
Business Profile[1]
Fabtech provides end-to-end turnkey pharma plant solutions covering design, engineering, procurement, installation, and regulatory validation, while also offering standalone execution services like equipment supply and installation for clients with their own designs.